학술논문

Brigatinib efficacy and safety in patients (Pts) with anaplastic lymphoma kinase (ALK)-positive (ALK+) non-small cell lung cancer (NSCLC) in a phase 1/2 trial: 1330
Document Type
Academic Journal
Source
Journal of Thoracic Oncology. Apr 01, 2016 11(4 Suppl):S114-S114
Subject
Language
English
ISSN
1556-0864